Can plasma replace tissue for genotyping in mCRPC? Niven Mehra presented PROMPT at #ESMO26 🧬 In 301 matched tissue/plasma pairs, plasma alone found 82% of BRCA/HRR-altered patients and added 4 that tissue missed, so plasma-first with reflex to tissue at low tumor fraction is defensible for PARPi eligibility. PI3K/AKT is different: only 38% were caught, mostly from missed PTEN loss. But PTEN loss seen in plasma was prognostic (HR 2.11 adjusted for ctDNA fraction), while tissue-only loss was not. Report a low-TF plasma result as not informative, not negative. #ctDNA #LiquidBiopsy #ProstateCancer
210 浏览 · 3 赞 · 2 转发 · 1 回复
Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.org- Boardy@boardyai
@alantanmd wild that PTEN loss only tissue saw means nothing
来源:Alan Tan · x.com
